Advanced Search
ORIGINAL ARTICLE
Korean J Pediatr 2009 February;52(2) :181-186.
doi:https://doi.org/10.3345/kjp.2009.52.2.181
Montelukast as an add-on therapy in bronchopulmonary dysplasia
He Min Kim (Kim HM), Ji Eun Song (Song JE), Soon Min Lee (Lee SM), Min Soo Park (Park MS), Kook In Park (Park KI), Ran Namgung (Namgung R), Chul Lee (Lee C)
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
Corresponding Author: Min Soo Park ,Email: minspark@yumc.yonsei.ac.kr
Copyright © 2009 by The Korean Pediatric Society
ABSTRACT
Purpose : Inflammation plays a potential role in the pathogenesis of bronchopulmonary dysplasia (BPD). Strategies for preventing BPD include respiratory management, antioxidants, nutritional treatment, and others such as anti-inflammatory agents. We aimed to assess the safety, tolerability, and efficacy of montelukast (MK), a cysteinyl leukotriene 1 receptor antagonist, as an add-on therapy in BPD. Methods : In addition to currently available standard measures such as oxygen supplementation, bronchodilators, nutritional support, and/or diuretics, montelukast was administered to 15 preterm infants with BPD. MK was given orally (1 mg/ kg/d) for a mean period of 12 weeks. We compared safety and efficacy parameters with historical controls. Results : All 15 patients survived, and no differences were found in the incidence of adverse reactions between the 2 groups. The ventilation index was significantly improved after 2 weeks in MK group compared with historical controls. There were no significant differences in other respiratory parameters (MAP, oxygen dependency, and ventilator dependency) between the groups, but the MK group showed trends of greater improvement. Conclusion : Administration of MK 1 mg/kg/d was well tolerated in preterm BPD patients as an add-on therapy. We demonstrated that after 2 weeks of MK administration of 1 mg/kg/d, MK had beneficial therapeutic effects on BPD patients as an add-on to the standard therapy. Further multicenter randomized controlled clinical trials are needed to confirm the efficacy and safety of MK as a useful supplement to standard therapy for BPD patients.
Keywords: Bronchopulmonary dysplasia | Montelukast | Safety | Efficiency
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail
Share:      
METRICS
1,961
View
7
Download
Chorioamnionitis: Is a major player in the development of bronchopulmonary dysplasia?  2017 July;60(7)
The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia  2015 September;58(9)
Bronchopulmonary Dysplasia  1994 May;37(5)
Risk Factors and Outcome of Bronchopulmonary Dysplasia  1994 January;37(1)
The Therapeutic Effects of Dexamethasone in Bronchopulmonary Dysplasia  1993 December;36(12)
Register for e-submission
Register here to access the e-submission system of Korean J Pediatr for authors and reviewers.
Manuscript Submission
To submit a manuscript, please visit the Korean J Pediatr e-submission management system at http://submit.kjp.or.kr, read the Instructions for Authors, and log into the Korean J Pediatr e-submission system. For assistance with manuscript submission, please contact: kjpped@gmail.com.
Free archive
Anyone may access any past or current articles without logging in.
Korean Pediatric Society Office
#1606, Seocho World Officetel, 19 Seoun-ro, Seocho-gu, Seoul 137-070, Korea
TEL : +82-2-3473-7305    FAX : +82-2-3473-7307   E-mail: kjpped@gmail.com
BrowseCurrent IssueFor Authors and ReviewersAbout
Copyright© The Korean Pediatric Society. All right reserved.